Article

UC Davis receives AMD grant

University of California, Davis researchers have received a 3-year, $1.8 million grant from the National Eye Institute to study the cellular changes that cause age-related macular degeneration.

Sacramento, CA-University of California, Davis (UC Davis) researchers have received a 3-year, $1.8 million grant from the National Eye Institute (NEI) to study the cellular changes that cause age-related macular degeneration (AMD).

With this funding, UC Davis researchers will look at how the retinal pigment epithelium (RPE) is affected by epigenetic factors-changes that alter gene expression while leaving the original genome sequence intact. Preliminary research by the team showed that the expression in several genes important to RPE cells changes with age.

“We want to know the biochemical changes in retinal cells that occur with aging and increase the susceptibility for this disease,” said Larry Hjelmeland, PhD, principal investigator on the grant and professor of ophthalmology with the UC Davis Eye Center.

“Looking at aging as an epigenetic phenomenon clearly represents a big step forward for the study of AMD,” added Dr. Hjelmeland, whose project is one of the first to be funded by the NEI to explore the link between epigenetics and eye disease.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.